All In Biotech

Drug Trial Radar · NCT03729362

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease Compared With Alglucosidase Alfa/Placebo

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Dec 4, 2018

Primary completion

Dec 15, 2020

Study completion Jan 15, 2021

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3 double-blind randomized study to study the efficacy and safety of intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe Disease compared with Alglucosidase Alfa/placebo.

Conditions

  • Pompe Disease (Late-onset)

Interventions

  • Cipaglucosidase AlfaBiological

    Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).

  • MiglustatDrug

    Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.

  • Alglucosidase AlfaBiological

    Participants received an IV infusion dose over a 4-hour duration Q2W.

  • PlaceboDrug

    Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 52 in 6 Minute Walk Distance (6MWD)Time frame: Baseline, Week 52

Locations

73 sites in 24 countries. Site status is shown where the registry gives one.

  • Neuromuscular Research Center

    Phoenix, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • University of California, Irvine

    Irvine, California

  • UF Helath: University of Florida Clinical Research Center

    Gainesville, Florida

  • University of South Florida Research Center

    Tampa, Florida

  • Emory Clinic

    Atlanta, Georgia

  • Indiana University Health Neuroscience Center

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Minnesota Clinical Research Unit

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Billings Clinic

    Billings, Montana

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • The Feinstein Institute for Medical Research

    Manhasset, New York

  • NYU School of Medicine

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Neurology

    Cincinnati, Ohio

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Texas Health Science Center San Antonio

    San Antonio, Texas

  • University of Utah, Center for Clinical and Translational Sciences

    Salt Lake City, Utah

  • Lysosomal and Rare Disorders Research

    Fairfax, Virginia

  • Hospital Universitario Austral

    Buenos Aires, Argentina

  • Westmead Hospital

    Westmead, Australia

  • Royal Brisbane & Women's Hospital

    Herston, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Monash Medical Centre

    Melbourne, Victoria, Australia

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • UZ Leuven

    Leuven, Belgium

  • University Clinical Centre of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • UMHAT Alexandrovska

    Sofia, Bulgaria

  • Heritage Medical Research Clinic, University of Calgary

    Calgary, Alberta, Canada

  • McMaster University Medical Centre

    Hamilton, Ontario, Canada

  • Aarhus Universitets Hospital

    Aarhus N, Denmark

  • Rigshospitalet Copenhagen Neuromuscular Center

    Copenhagen, Denmark

  • Hôpital Neurologique Pierre Wertheimer

    Bron, France

  • Hôpital Raymond Poincaré

    Garches, France

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.